Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
PEPG | US
-0.06
-4.26%
Healthcare
Biotechnology
30/06/2024
08/06/2026
1.35
1.43
1.43
1.35
PepGen Inc. a clinical-stage biotechnology company focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51 an EDO peptide that id in Phase I clinical trial to treat individuals with Duchenne muscular dystrophy (DMD). The company is also developing PGN-EDODM1 an EDO peptide-conjugated PMO which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1 as well as EDO therapeutic candidates such as PGN-EDO53 PGN-EDO45 and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is headquartered in Boston Massachusetts.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
41.2%1 month
64.7%3 months
133.4%6 months
120.7%-
-
1.88
0.13
0.10
-3.11
-
-
-94.36M
44.00M
44.00M
-
-
-
-
-58.97
7.73
5.64
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.21
Range1M
0.47
Range3M
5.37
Rel. volume
0.67
Price X volume
640.51K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Mereo BioPharma Group plc | MREO | Biotechnology | 0.305 | 46.93M | -2.62% | n/a | 7.83% |
| Nuo Therapeutics Inc | AURX | Biotechnology | 1 | 46.60M | -13.79% | n/a | 0.00% |
| NRXP | NRXP | Biotechnology | 4.33 | 46.55M | 4.59% | n/a | -46.73% |
| INC Research Holdings Inc | INCR | Drug Manufacturers-Specialty & Generic | 0.99 | 45.31M | -2.94% | n/a | 28.90% |
| BioXcel Therapeutics Inc | BTAI | Biotechnology | 1.105 | 45.02M | 0.00% | n/a | -139.46% |
| Acrivon Therapeutics Inc. | ACRV | Biotechnology | 1.41 | 43.67M | -1.40% | n/a | 1.95% |
| Entera Bio Ltd | ENTX | Biotechnology | 1.2 | 43.59M | 1.69% | n/a | 3.91% |
| QNCX | QNCX | Biotechnology | 1 | 43.28M | -0.99% | n/a | 30.62% |
| Gain Therapeutics Inc. Common Stock | GANX | Biotechnology | 1.69 | 43.15M | -0.59% | n/a | 6.85% |
| Clene Nanomedicine Inc | CLNN | Biotechnology | 5.33 | 42.44M | -2.20% | n/a | -6472.02% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 21.08 | 32.10M | -0.02% | n/a | 204.46% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 1.1 | 16.07M | 7.84% | 0.03 | 16.03% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.4131 | 7.98M | -3.48% | n/a | 58.43% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.49 | 3.81M | 12.88% | n/a | 17.32% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0058 | 534.84K | n/a | -37.05% | |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 0.4181 | 230.37K | 7.87% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.11 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.88 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 133.44 | 72.80 | Riskier |
| Debt to Equity | 0.13 | -1.23 | Expensive |
| Debt to Assets | 0.10 | 0.25 | Cheaper |
| Market Cap | 44.00M | 3.66B | Emerging |